Overview

This trial is active, not recruiting.

Condition leukemia
Treatments decitabine, carboplatin, arsenic trioxide
Phase phase 2
Sponsor M.D. Anderson Cancer Center
Collaborator TEVA
Start date July 2014
End date July 2026
Trial size 120 participants
Trial identifier NCT02188706, 2013-0543, CA100632, NCI-2014-01576

Summary

The goal of this clinical research study is to compare the response rates of patients receiving decitabine alone, decitabine with carboplatin, and decitabine with arsenic trioxide in patients with AML or MDS.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Decitabine 20 mg/m2 by vein daily over 1 hour for 5 days every 4 weeks.
decitabine Dacogen
20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
(Experimental)
Decitabine 20 mg/m2 by vein daily over 1 hour for 5 days every 4 weeks. Carboplatin AUC 5 by vein over 1 hour on day 8 (+/- 2 days) repeated every 4 weeks.
decitabine Dacogen
20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
carboplatin Paraplatin
AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
(Experimental)
Decitabine 20 mg/m2 by vein daily over 1 hour for 5 days every 4 weeks. Arsenic Trioxide 0.15 mg/kg by vein over 1 hour for 5 days, repeated every 4 weeks (+/- 2 days).
decitabine Dacogen
20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
arsenic trioxide ATO
0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.

Primary Outcomes

Measure
Overall Response
time frame: 28 days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Patients with AML, relapsed or refractory to standard therapy or elderly patients with AML (age 65 or over). Patients who have AML and are younger than age 65 but considered unfit for conventional chemotherapy are eligible. Patients with de novo or treated MDS or CMML INT-1 or above are eligible. Patients may have had prior exposure to azacitidine but no more than one cycle of decitabine. Patients must have been off chemotherapy for 2 weeks prior to entering this study and have recovered from the toxicities of that therapy; A caveat to this is in the case of rapidly progressive disease. Hydroxyurea is permitted for control of elevated WBC prior to treatment and can be continued for the first 4 weeks of therapy. Erythropoiesis stimulating agents (ESAs) and GCSF are allowed before therapy. ESAs, GCSF or other growth factors are permitted on therapy. 2. Performance 0-2 (ECOG). 3. Adequate cardiac functions assessed by 2D ECHO (NYHA cardiac III-IV excluded). 4. Pre-treatment EKG 5. Adequate end organ function with creatinine stage 3. 5. HIV infection.

Additional Information

Official title Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Principal investigator Hagop Kantarjian, MD
Description Study Groups: If you are found to be eligible to take part in this study and you are one of the first 30 participants enrolled, you will have an equal chance of being in one of 3 study groups. If you enroll after the first 30 participants are enrolled, you will have a higher chance of being assigned to the group is having better results. - If you are in Group 1, you will receive decitabine alone. - If you are in Group 2, you will receive decitabine and carboplatin. - If you are in Group 3, you will receive decitabine and arsenic trioxide. Study Drug Administration: Every 4 weeks is a study cycle. You will receive decitabine by vein over about 1 hours on Days 1-5 of each cycle. If you are receiving carboplatin, you will receive it over 1 hour on Day 8 (+/-2 days) of each cycle. If you are receiving arsenic trioxide, you will receive it over about 1 hour on Days 1-5 of each cycle Study Visits: Blood (about 1-2 teaspoons) will be drawn 1-2 times a week during Cycle 1 and then every 2-4 weeks after that for routine tests. If you have stable disease, blood will only be drawn every 4-6 weeks. On Day 28 of Cycle 3 (+/- 3 days), you will have a bone marrow aspirate and biopsy to check the status of the disease. After that, you will have bone marrow biopsies/aspirations when the doctor thinks it is needed. If you are in Group 3, you will have EKGs on Day 1 of each cycle before receiving the study drugs. On Days 1 and 4 of each cycle, blood (about 1-2 teaspoons) will also be drawn for routine tests before your dose of the study drugs. If you are taken off study, blood (about 1-2 teaspoons) will be drawn for routine tests. Length of Study: You may continue taking the study drugs for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drug(s) if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. This is an investigational study. Arsenic trioxide is FDA approved and commercially available for the treatment of APL. Decitabine is FDA approved and commercially available for the treatment of MDS. Carboplatin is FDA approved and commercially available for the treatment solid tumors. The study drug or study drug combination you receive on this study are considered investigational. Up to 120 patients will take part in this study. Up to 20 patients will be enrolled at MD Anderson.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by M.D. Anderson Cancer Center.